Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

NEW INDICATIONS

Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On October 1, 2021, the FDA accelerated the approval of a new indication for brexucabtagene autoleucel (Tecartus; Kite Pharma), a CD19-directed CAR T-cell therapy, for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The FDA granted brexucabtagene autoleucel breakthrough therapy and orphan drug designations for this indication.

This approval was based on the ZUMA-3 study, a single-arm multicenter clinical trial of adults with relapsed or refractory B-cell precursor ALL. Patients received a single infusion of brexucabtagene autoleucel after completion of lymphodepleting chemotherapy.

The efficacy measures were complete response (CR) within 3 months after receiving the CAR T-cell infusion, and the duration of the CR. Of the 54 patients evaluable for efficacy, 28 (52%; 95% confidence interval, 38-66) achieved CR within 3 months. At a median follow-up of 7.1 months, the median duration of CR was not reached, and the duration of CR was estimated to be >12 months for >50% of the patients.

The most common (≥20%) nonlaboratory side effects included fever, cytokine-release syndrome, hypotension, encephalopathy, tachycardias, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting.

Related Items
Cytalux, a Novel Imaging Agent, FDA Approved for Diagnosing Inoperable Ovarian Cancer Lesions
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Oral Scemblix FDA Approved for Patients with Ph-Positive Chronic Myeloid Leukemia
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Darzalex Faspro, Kyprolis, and Dexamethasone a New Combination FDA Approved for Multiple Myeloma
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Keytruda Now FDA Approved for Adjuvant Treatment of Renal-Cell Carcinoma
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Tecentriq First Immunotherapy FDA Approved for Adjuvant Treatment of Early-Stage Non–Small-Cell Lung Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Keytruda plus Chemotherapy FDA Approved for First-Line Treatment of Cervical Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Verzenio with Endocrine Therapy FDA Approved for Adjuvant Treatment of Early Breast Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Oncology Update
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.